文献速递神经MR

酰胺质子转移成像鉴别复发性弥漫性胶质瘤与治疗所致改变:对扩散和灌注参数的增量价值

Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters.
PubMed 文献 · Neuroradiology · 2020-09-02

本研究纳入36例治疗后胶质瘤患者(25例复发、11例治疗所致改变),评估ADC、FA、nCBV、nCBF、Ktrans、Kep、Ve、Vp及APT不对称指数的鉴别价值。单因素分析显示较低ADC、较高FA、较高nCBV和较高APT信号与复发相关;多因素模型中加入APT信号后AUC由0.87升至0.92,NRI为0.77、IDI为0.13。作者认为APT成像可能是有用的影像生物标志物,可为DTI、DCE和DSC参数增加鉴别价值。

要点

  • APT信号升高与胶质瘤复发相关(p=0.009),可辅助鉴别治疗所致改变。
  • ADC、FA、nCBV联合模型加入APT后AUC由0.87升至0.92。
  • 复发组表现为较低ADC、较高FA、较高nCBV及较高APT信号。

核心结论

  • APT成像可能是有用的影像生物标志物,可为DTI、DCE和DSC参数增加鉴别复发性胶质瘤与治疗所致改变的价值。

研究设计与样本

  • 单中心研究纳入36例治疗后胶质瘤患者,其中25例为复发性胶质瘤、11例为治疗所致改变,评估ADC、FA、nCBV、nCBF、Ktrans、Kep、Ve、Vp及APT不对称指数。
  • 采用多因素logistic回归筛选独立预测复发性胶质瘤的定量参数。
  • 通过AUC增加、净重分类指数和综合判别改善指数评估APT信号对其他参数的增量价值。

诊断标准与关键数值

  • 单因素分析显示较低ADC(p=0.018)、较高FA(p=0.031)、较高nCBV(p=0.021)和较高APT信号(p=0.009)与复发性胶质瘤相关。
  • 含ADC、FA和nCBV的模型AUC为0.87,加入APT信号后AUC为0.92,净重分类指数为0.77,综合判别改善指数为0.13。

临床应用与阅片要点

  • 作者认为APT成像可能作为附加影像生物标志物,与DTI、DCE和DSC参数联合用于鉴别复发性胶质瘤与治疗所致改变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the incremental value of amide proton transfer (APT) imaging to diffusion tensor imaging (DTI), dynamic susceptibility contrast (DSC) imaging, and dynamic contrast-enhanced (DCE) imaging in differentiating recurrent diffuse gliomas (World Health Organization grade II-IV) from treatment-induced change after concurrent chemoradiotherapy or radiotherapy.

METHODS: This study included 36 patients (25 patients with recurrent gliomas and 11 with treatment-induced changes) with post-treatment gliomas. The mean values of apparent diffusion coefficient (ADC), fractional anisotropy (FA), normalized cerebral blood volume (nCBV), normalized cerebral blood flow, volume transfer constant, rate transfer coefficient, extravascular extracellular volume fraction, plasma volume fraction, and APT asymmetry index were assessed. Independent quantitative parameters were investigated to predict recurrent glioma using multivariable logistic regression. The incremental value of APT signal to other parameters was assessed by the increase of the area under the curve, net reclassification index, and integrated discrimination improvement.

RESULTS: Univariable analysis showed that lower ADC (p = 0.018), higher FA (p = 0.031), higher nCBV (p = 0.021), and higher APT signal (p = 0.009) were associated with recurrent gliomas. In multivariable logistic regression, the diagnostic performance of the model with ADC, FA, and nCBV significantly increased when APT signal was added, with areas under the curve of 0.87 and 0.92, respectively (net reclassification index of 0.77 and integrated discrimination improvement of 0.13).

CONCLUSION: APT imaging may be a useful imaging biomarker that adds value to DTI, DCE, and DSC parameters for distinguishing between recurrent gliomas and treatment-induced changes.

来源:Neuroradiology,查看原文。版权归原作者所有。

引用

  1. Park YW, Ahn SS, Kim EH, et al. Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology. 2020. PMID: 32879995. doi:10.1007/s00234-020-02542-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。